vs
PHIBRO ANIMAL HEALTH CORP（PAHC）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
PHIBRO ANIMAL HEALTH CORPの直近四半期売上が大きい（$373.9M vs $188.3M、BRC Group Holdings, Inc.の約2.0倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 7.3%、差は40.6%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs -21.9%）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs -15.4%）
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
PAHC vs RILY — 直接比較
売上が大きい
PAHC
2.0倍大きい
$188.3M
売上成長率が高い
PAHC
+42.8%の差
-21.9%
純利益率が高い
RILY
純利益率が40.6%高い
7.3%
2年売上CAGRが高い
PAHC
2年複合成長率
-15.4%
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $373.9M | $188.3M |
| 純利益 | $27.5M | $90.3M |
| 粗利率 | 35.5% | 79.5% |
| 営業利益率 | 13.5% | 32.3% |
| 純利益率 | 7.3% | 47.9% |
| 売上前年比 | 20.9% | -21.9% |
| 純利益前年比 | 762.1% | 1710.8% |
| EPS（希薄化後） | $0.67 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上PAHCRILY
| Q4 25 | $373.9M | $188.3M | ||
| Q3 25 | $363.9M | $215.3M | ||
| Q2 25 | $378.7M | $188.2M | ||
| Q1 25 | $347.8M | $197.2M | ||
| Q4 24 | $309.3M | $241.0M | ||
| Q3 24 | $260.4M | $225.5M | ||
| Q2 24 | $273.2M | $256.0M | ||
| Q1 24 | $263.2M | $263.4M |
純利益PAHCRILY
| Q4 25 | $27.5M | $90.3M | ||
| Q3 25 | $26.5M | $91.1M | ||
| Q2 25 | $17.2M | $139.5M | ||
| Q1 25 | $20.9M | $-10.0M | ||
| Q4 24 | $3.2M | $-5.6M | ||
| Q3 24 | $7.0M | $-284.4M | ||
| Q2 24 | $752.0K | $-433.6M | ||
| Q1 24 | $8.4M | $-49.2M |
粗利率PAHCRILY
| Q4 25 | 35.5% | 79.5% | ||
| Q3 25 | 32.9% | 83.7% | ||
| Q2 25 | 29.0% | 81.3% | ||
| Q1 25 | 30.1% | 81.4% | ||
| Q4 24 | 32.9% | 79.8% | ||
| Q3 24 | 32.1% | 82.1% | ||
| Q2 24 | 31.9% | 84.5% | ||
| Q1 24 | 30.2% | 85.3% |
営業利益率PAHCRILY
| Q4 25 | 13.5% | 32.3% | ||
| Q3 25 | 14.1% | 30.4% | ||
| Q2 25 | 8.9% | 5.7% | ||
| Q1 25 | 9.6% | -31.2% | ||
| Q4 24 | 8.3% | -69.2% | ||
| Q3 24 | 6.8% | -36.4% | ||
| Q2 24 | 6.7% | -90.8% | ||
| Q1 24 | 7.6% | -6.1% |
純利益率PAHCRILY
| Q4 25 | 7.3% | 47.9% | ||
| Q3 25 | 7.3% | 42.3% | ||
| Q2 25 | 4.5% | 74.1% | ||
| Q1 25 | 6.0% | -5.1% | ||
| Q4 24 | 1.0% | -2.3% | ||
| Q3 24 | 2.7% | -126.1% | ||
| Q2 24 | 0.3% | -169.4% | ||
| Q1 24 | 3.2% | -18.7% |
EPS（希薄化後）PAHCRILY
| Q4 25 | $0.67 | $2.78 | ||
| Q3 25 | $0.65 | $2.91 | ||
| Q2 25 | $0.43 | $4.50 | ||
| Q1 25 | $0.51 | $-0.39 | ||
| Q4 24 | $0.08 | $-0.01 | ||
| Q3 24 | $0.17 | $-9.39 | ||
| Q2 24 | $0.02 | $-14.35 | ||
| Q1 24 | $0.21 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $74.5M | $226.6M |
| 総負債低いほど良い | $624.2M | $1.4B |
| 株主資本純資産 | $332.4M | $-171.5M |
| 総資産 | $1.4B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 1.88× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資PAHCRILY
| Q4 25 | $74.5M | $226.6M | ||
| Q3 25 | $85.3M | $184.2M | ||
| Q2 25 | $77.0M | $267.4M | ||
| Q1 25 | $70.4M | $138.3M | ||
| Q4 24 | $67.1M | $146.9M | ||
| Q3 24 | $89.8M | $159.2M | ||
| Q2 24 | $114.6M | $236.9M | ||
| Q1 24 | $98.7M | $190.7M |
総負債PAHCRILY
| Q4 25 | $624.2M | $1.4B | ||
| Q3 25 | $628.0M | $1.3B | ||
| Q2 25 | $631.7M | $1.3B | ||
| Q1 25 | $635.4M | $1.4B | ||
| Q4 24 | $639.1M | $1.5B | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
株主資本PAHCRILY
| Q4 25 | $332.4M | $-171.5M | ||
| Q3 25 | $311.7M | $-260.5M | ||
| Q2 25 | $285.7M | $-351.7M | ||
| Q1 25 | $266.0M | $-496.8M | ||
| Q4 24 | $246.8M | $-488.2M | ||
| Q3 24 | $258.5M | $-497.6M | ||
| Q2 24 | $256.6M | $-218.3M | ||
| Q1 24 | $270.1M | $228.4M |
総資産PAHCRILY
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $966.3M | $2.2B | ||
| Q2 24 | $982.2M | $3.2B | ||
| Q1 24 | $979.0M | $5.0B |
負債/資本比率PAHCRILY
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.4M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.3M | — |
| FCFマージンFCF / 売上 | 2.2% | — |
| 設備投資強度設備投資 / 売上 | 3.0% | — |
| キャッシュ転換率営業CF / 純利益 | 0.70× | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $47.3M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローPAHCRILY
| Q4 25 | $19.4M | $26.2M | ||
| Q3 25 | $9.3M | $-60.6M | ||
| Q2 25 | $21.3M | $-25.6M | ||
| Q1 25 | $43.2M | $184.0K | ||
| Q4 24 | $3.1M | $-2.7M | ||
| Q3 24 | $12.6M | $19.5M | ||
| Q2 24 | $28.4M | $111.5M | ||
| Q1 24 | $11.4M | $135.4M |
フリーキャッシュフローPAHCRILY
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.7M | — |
FCFマージンPAHCRILY
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 0.6% | — |
設備投資強度PAHCRILY
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.7% | — |
キャッシュ転換率PAHCRILY
| Q4 25 | 0.70× | 0.29× | ||
| Q3 25 | 0.35× | -0.66× | ||
| Q2 25 | 1.24× | -0.18× | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 37.80× | — | ||
| Q1 24 | 1.36× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
